TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Telomir Pharmaceuticals, Inc. ( (TELO) ) has issued an announcement.
Telomir Pharmaceuticals, Inc. has reported new preclinical data on its compound Telomir-1, which shows promising results in reducing prostate-specific antigen (PSA) levels in human prostate cancer cells. The study found that Telomir-1 lowered PSA levels in a dose-related manner and was also linked to decreased cellular energy metabolism and viability. Additionally, in a mouse model study, Telomir-1 reduced tumor volume as a single agent and, when combined with paclitaxel, achieved full tumor reduction without treatment-related mortality, unlike paclitaxel alone which had a high mortality rate. These findings support Telomir Pharmaceuticals’ ongoing preclinical development of Telomir-1 across various conditions and its preparation for regulatory submissions.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Average Trading Volume: 3,109,427
Technical Sentiment Signal: Sell
Current Market Cap: $44.01M
For a thorough assessment of TELO stock, go to TipRanks’ Stock Analysis page.